Interims show strong progress towards the launch of the CSD500 condom through multiple partners in 2016. Combined with the expected H2 launch of MED2002 as a UK Special and potential partnering deals for the company’s topical pain relief products, this bodes for an exciting year ahead. We have downgraded forecasts to reflect the delayed condom launch by C&D in Europe and Kabey Consumer Health. However, near-term partnering deals could potentially drive substantial valuation upside.
09 Sep 2015
Interim results highlight development progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interim results highlight development progress
Futura Medical plc (FUM:LON) | 35.7 -0.1 (-0.8%) | Mkt Cap: 107.7m
- Published:
09 Sep 2015 -
Author:
N+1 Singer Team -
Pages:
4
Interims show strong progress towards the launch of the CSD500 condom through multiple partners in 2016. Combined with the expected H2 launch of MED2002 as a UK Special and potential partnering deals for the company’s topical pain relief products, this bodes for an exciting year ahead. We have downgraded forecasts to reflect the delayed condom launch by C&D in Europe and Kabey Consumer Health. However, near-term partnering deals could potentially drive substantial valuation upside.